曲格列汀（Trelagliptin）100mg
1. Composition:
The chemical name of Omarigliptin is (S)-2-[(2S)-2-amino-3-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)-1-oxopropyl]piperidine-3-carboxamide. It exerts its glucose-lowering effect by inhibiting the DPP-4 enzyme and is commonly used in a 100mg dose to treat adults with type 2 diabetes.
2. Pharmacodynamics:
Omarigliptin, as a DPP-4 inhibitor, works by inhibiting the DPP-4 enzyme, extending the half-life of incretins (like GLP-1), promoting insulin secretion, and inhibiting glucagon secretion, helping lower blood glucose levels, particularly postprandial glucose. Its uniqueness lies in its once-weekly dosing frequency, which, compared to other DPP-4 inhibitors (such as Sitagliptin, which requires daily dosing), offers better patient adherence.
3. Usage Instructions:
Omarigliptin is typically taken orally in the form of 100mg tablets, recommended once a week. Patients should take the medication on the same day and at the same time each week, either before or after meals. Missed doses should be taken as soon as possible, and subsequent doses should not be increased.
4. Research & Development History:
Omarigliptin was developed by Takeda Pharmaceutical Company in Japan and was first approved by Japan's Ministry of Health, Labour and Welfare in 2015 for the treatment of type 2 diabetes. Its introduction filled the gap for once-weekly DPP-4 inhibitors, making it an innovative option in diabetes treatment.
5. Mechanism of Action:
Omarigliptin reduces the degradation of incretins (such as GLP-1 and GIP) by inhibiting the activity of the enzyme dipeptidyl peptidase-4 (DPP-4). Incretins promote insulin secretion and reduce glucagon secretion, thereby lowering blood glucose levels. Its long-acting properties allow for once-weekly administration while maintaining stable glucose-lowering effects.
6. Summary :
Omarigliptin is a long-acting DPP-4 inhibitor suitable for glycemic control in patients with type 2 diabetes. Its once-weekly dosing improves patient adherence while extending the action of incretins to enhance blood glucose control. Omarigliptin has good safety and tolerability, with relatively few side effects, making it suitable for patients who require long-term blood glucose management.
